Sandra Black, MD, FRCP(C) is an internationally renowned cognitive and stroke neurologist who holds the inaugural Brill Chair in Neurology, Department of Medicine, University of Toronto and Sunnybrook Health Sciences Centre. A leading clinical trialist in dementia, she is the current Executive Director of the Toronto Dementia Research Alliance, a multi institutional collaborative network of memory programs at the University of Toronto involving Baycrest, Centre for Addiction and Mental Health, St. Michael’s Hospital, Sunnybrook HSC and Toronto Western Hospital, UHN. She is also the Sunnybrook Site Director of the Heart & Stroke Foundation Canadian Partnership for Stroke Recovery and the Hurvitz Brain Sciences Research Program Director at Sunnybrook Research Institute. In 2011 she was named to the Order of Ontario, cited as an assiduous physician leader and influential architect of the Ontario Stroke System. She has authored/co-authored over 450 papers in a 25-year research career that has bridged dementia and stroke, using neuroimaging to study brain behavior relationships, with a recent focus on interactions of Alzheimer’s and silent stroke disease. She has earned numerous mentorship and research awards, and elected to the Royal Society of Canada in 2012. In 2015 she received the U of T Faculty of Medicine Dean’s Alumni Lifetime Achievement Award and was appointed an Officer to the Order of Canada for her contributions to Alzheimer’s disease, stroke and vascular dementia.
Sandra Black, MD, FRSC, OC, Oont
Affiliate Scientist, KITE (TRI)
dementia, apraxia, stroke recovery, neurorehabilitation, vascular cognitive impairment, cognitive neuroscience, neurodegenerative disorders, Lewy body dementia, frontotemporal dementia, neuroimaging biomarkers, cerebral small vessel disease, brain imaging analysis, Alzheimer disease, primary progressive aphasia (PPA)
Dr. Black's research foci include the following:
- Mild cognitive impairment and Alzheimer’s disease
- Vascular cognitive impairment and cerebral small vessel disease
- Parkinson’s disease, Lewy body spectrum disorder and frontotemporal dementia (behavioural variant, primary progressive aphasia)
- Apraxia and aphasia
- Stroke recovery
- Clinical trials in dementia and its prevention
- Neuroimaging biomarkers and brain-behaviour relationships
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design.
Can J Cardiol. 2019 Aug;35(8):1069-1077
Neuroimage Clin. 2019 Jul 18;24:101943
Clin Nucl Med. 2019 Jul 24;:
Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.
Contemp Clin Trials Commun. 2019 Sep;15:100385
Alzheimers Dement. 2019 Jul;15(7):961-984
24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
J Alzheimers Dis. 2019 Jul 16;:
Can J Neurol Sci. 2019 Jul 16;:1-13
Resting state functional connectivity changes after MR-guided focused ultrasound mediated blood-brain barrier opening in patients with Alzheimer's disease.
Neuroimage. 2019 Jun 26;200:275-280
Am J Geriatr Psychiatry. 2019 May 08;:
Optical Coherence Tomography as an Adjunct During Carotid Artery Stenting for Carotid Atherosclerotic Disease.
Clin Neuroradiol. 2019 May 31;:
Affiliate Scientist, KITE (TRI)
Brill Chair in Neurology, University of Toronto, Sunnybrook Health Sciences Centre